Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Gynecologic Cancer

MDX-1105 for Advanced or Recurrent Cancer (UW08038)
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors
Status Conditions Phase Study ID
Closed Renal Cell Carcinoma
Non-small Cell Lung Cancer
Malignant Melanoma
Epithelial Ovarian Cancer
Phase I UW08038
NCT00729664
Summary

The primary purpose of this study is to determine if MDX-1105 is safe and tolerated when administered every 14 days to subjects with selected advanced or recurrent solid tumors.


Investigator
Scott S. Tykodi, MD, PhD
Location    
SCCA Phase 1 Program Office 206-288-7551 Refer Patient
Eligibility Criteria (must meet the following to participate in this study)
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ECOG PS 0 to 2
  • Relapsed/refractory renal cell carcinoma,NSCLC,malignant melanoma, epithelial ovarian cancer
  • Up to 5 previous systemic therapies
  • Must have measurable disease

Exclusion Criteria:

  • No history of severe hypersensitivity reactions to other monoclonal antibodies
  • No prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody
  • No active infection (viral, bacterial or fungal)
  • No active autoimmune disease or a documented history of autoimmune
  • No active or latent infection
Last Updated
September 15, 2014
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.